Albireo Pharma, Inc. (ALBO)
(Delayed Data from NSDQ)
$36.36 USD
+1.29 (3.68%)
Updated May 3, 2019 04:00 PM ET
After-Market: $36.19 (%) 5:22 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
0 items in cart
[ALBO]
Reports for Purchase
Showing records 1 - 20 ( 381 total )
Industry: Medical - Biomedical and Genetics
Price: 5.00
Industry: Medical - Biomedical and Genetics
Price: 5.00
Industry: Medical - Biomedical and Genetics
Fortune Favors the BOLD: Assessing the Opportunity in Biliary Atresia
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Price: 12.50
Industry: Medical - Biomedical and Genetics
FDA Accepts Bylvay sNDA for ALGS; We Expect Approval By June 15th PDUFA Date; Maintain Neutral on Ipsen Acquisition
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Industry: Medical - Biomedical and Genetics
Bylvay/ALGS sNDA Accepted for Priority Review, PDUFA Set to June 15, 2023
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Price: 12.50
Industry: Medical - Biomedical and Genetics
Albireo Enters Into Definitive Merger Agreement With Ipsen At 104% Premium; Downgrading to Neutral With $42 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50
Industry: Medical - Biomedical and Genetics
Price: 12.50
Industry: Medical - Biomedical and Genetics
Bylvay''s Best-in-Class Profile Backed by Ipsen Acquisition; D/g to NEUTRAL
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Price: 12.50
Industry: Medical - Biomedical and Genetics
2023 Outlook - New Commercial Launches, Clinical Catalysts & M&A Driving Value
Provider: Wedbush Securities Inc.
Analyst: Research Department
Price: 35.00
Industry: Medical - Biomedical and Genetics
Regulatory Filings Submitted For Bylvay''s Expansion Into ALGS; Decisions Expected in 2H23; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Industry: Medical - Biomedical and Genetics
KOL Call Highlights: Battle of the IBATi''s Building Up to Biliary Atresia
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Price: 12.50
Industry: Medical - Biomedical and Genetics
Price: 35.00
Industry: Medical - Biomedical and Genetics
Q3: PFIC Launch Gaining Momentum; Connecting the Dots to ALGS and BA
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Price: 12.50
Industry: Medical - Biomedical and Genetics
3Q Recap; AASLD Abstract Presentations Highlight Bylvay in PFIC and ALGS; ALGS Filings On Track in 1Q23; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50
Industry: Medical - Biomedical and Genetics
3Q Recap; Revised REMS Proposal For Sparsentan in IgAN Submitted; New PDUFA Date February 17, 2023; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Industry: Medical - Biomedical and Genetics
Price: 12.50
Industry: Medical - Biomedical and Genetics
Bylvay''s Efficacy, Safety and Dose Stands Strong Against Competitor PFIC Data
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Price: 12.50
Industry: Medical - Biomedical and Genetics
Price: 12.50
Industry: Medical - Biomedical and Genetics
NASPGHAN Highlights: Benefit of Earlier Bylvay Use in PFIC Patients
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Price: 12.50
Industry: Medical - Biomedical and Genetics
Positive Top-line Phase 3 ASSERT Data in ALGS Are Clear And Robust; Raise PT to $68
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50